BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20014934)

  • 21. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
    Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
    Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
    Caputo C; Prior D; Inder WJ
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabergoline and the risk of valvular lesions in endocrine disease.
    Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
    Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
    Valassi E; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
    Cawood TJ; Bridgman P; Hunter L; Cole D
    Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
    [No Abstract]   [Full Text] [Related]  

  • 28. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
    Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
    Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cabergoline-resistant prolactinoma patient: new challenges.
    Molitch ME
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
    [No Abstract]   [Full Text] [Related]  

  • 31. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
    Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
    Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of treatments for prolactinomas.
    Auriemma RS; Grasso LF; Pivonello R; Colao A
    Expert Opin Drug Saf; 2016; 15(4):503-12. PubMed ID: 26855238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
    Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
    J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
    Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
    Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
    Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
    Lebbe M; Hubinont C; Bernard P; Maiter D
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
    Samson SL; Ezzat S
    Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T; Härtter S; Burger E
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.